Illumina (NASDAQ:ILMN) Releases FY 2025 Earnings Guidance

Illumina (NASDAQ:ILMN) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided EPS guidance of 4.500-4.500 for the period, compared to the consensus EPS estimate of 4.510. The company issued revenue guidance of -. Illumina also updated its FY25 guidance to $4.50 EPS.

Illumina Trading Down 0.8 %

Illumina stock traded down $0.65 during mid-day trading on Monday, reaching $85.97. 2,988,392 shares of the company traded hands, compared to its average volume of 2,658,593. The firm’s 50 day moving average price is $118.38 and its 200 day moving average price is $131.48. Illumina has a 52-week low of $80.18 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The firm has a market capitalization of $13.62 billion, a price-to-earnings ratio of -11.19, a P/E/G ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, analysts anticipate that Illumina will post 4.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ILMN. Royal Bank of Canada dropped their price target on Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and dropped their target price for the company from $177.00 to $140.00 in a report on Friday, February 7th. Morgan Stanley decreased their price target on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 11th. Stephens lifted their price target on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Finally, HSBC cut shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective on the stock. in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Moderate Buy” and an average target price of $149.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.